High-frequency ventilation in preterm infants and neonates

Benjamin W. Ackermann, Daniel Klotz, Roland Hentschel, Ulrich H. Thome and Anton H. van Kaam

© The Author(s) 2021

High-frequency ventilation (HFV) has been used as a respiratory support mode for neonates for over 30 years. HFV is characterized by delivering tidal volumes close to or less than the anatomical dead space. Both animal and clinical studies have shown that HFV can effectively restore lung function, and potentially limit ventilator-induced lung injury, which is considered an important risk factor for developing bronchopulmonary dysplasia (BPD). Knowledge of how HFV works, how it influences cardiorespiratory physiology, and how to apply it in daily clinical practice has proven to be essential for its optimal and safe use. We will present important aspects of gas exchange, lung-protective concepts, clinical use, and possible adverse effects of HFV. We also discuss the study results on the use of HFV in respiratory distress syndrome in preterm infants and respiratory failure in term neonates.

Pediatric Research (2023) 93:1810–1818; https://doi.org/10.1038/s41390-021-01639-8

IMPACT:

- Knowledge of how HFV works, how it influences cardiorespiratory physiology, and how to apply it in daily clinical practice has proven to be essential for its optimal and safe use.
- Therefore, we present important aspects of gas exchange, lung-protective concepts, clinical use, and possible adverse effects of HFV.
- The use of HFV in daily clinical practice in lung recruitment, determination of the optimal continuous distending pressure and frequency, and typical side effects of HFV are discussed.
- We also present study results on the use of HFV in respiratory distress syndrome in preterm infants and respiratory failure in term neonates.

INTRODUCTION

High-frequency ventilation (HFV) is an exceptional invasive mechanical ventilation mode, in which gas transport and gas mixing are distinctly different from all other modes of mechanical ventilation. Developed by groups in Germany and Canada, HFV is characterized by the delivery of very small tidal volumes (VT) at supra-physiological frequencies. Animal studies have shown that ventilation with small VT, together with avoiding alveolar collapse, is one of the fundamental principles to minimize ventilator-induced lung injury (VILI). Preterm infants also benefitted from small tidal volumes compensated by higher ventilation rates. VILI is considered an important risk factor in the development of bronchopulmonary dysplasia (BPD). HFV has been considered a lung-protective ventilation modality since inspiratory overdistention due to large VT and end-expiratory lung collapse due to insufficient airway pressures may be more efficiently avoided than in conventional mechanical ventilation (CMV). For these reasons, HFV has been frequently used in neonatal care over the last 30 years.

Knowledge of how HFV works, how it impacts physiology, and how to apply it in daily clinical practice has proven to be essential for its optimal and safe use. This paper aims to review essential aspects of HFV and to summarize the available evidence for its therapeutic use in newborn infants.

BASIC PRINCIPLES

Gas exchange during HFV

Although the goals for gas exchange and avoiding VILI are similar during HFV and CMV, the mechanisms to accomplish these goals are fundamentally different.

During HFV, oxygenation is controlled by the continuous distending pressure (CDP) and the fraction of inspired oxygen (FiO2). Optimizing the end-expiratory lung volume (EELV) results in improved oxygenation by reducing atelectasis and intrapulmonary right-to-left shunts. Superimposed on the CDP, HFV generates oscillating pressure swings, resulting in oscillatory tidal volumes (VT) at supra-physiological frequencies between 8 and 15 Hz to clear CO2. The difference between the peak and trough of the pressure wave is referred to as the oscillatory pressure amplitude (ΔP0). Usually, the ΔP0 is dampened when moving from the Y-piece to the alveolar compartment by the inertance of the respiratory system. The V0 at the Y-piece is close to or smaller than anatomical dead space (1–3 ml/kg), the volume changes at the alveolar level are substantially diminished compared to VT in CMV. Ventilation takes place by oscillation-driven mixing of fresh residual gas by several physical mechanisms (Fig. 1).

Similar to CMV, V0 and frequency (f) are essential determinants for CO2 washout. However, the equation describing their contribution to ventilation is approximated by V0^2 * f, also referred to as the
Fig. 1 Various mechanisms of gas transport and pressure damping during high-frequency ventilation (HFV). In the trachea and main bronchi, HFV facilitates gas transport by convection, direct ventilation of close alveoli (bulk convection), and asymmetric inspiratory and expiratory velocity profiles. In the smaller bronchi and alveoli pendelluft, cardiogenic mixing, Taylor dispersion with laminar flow and molecular diffusion are the primary mechanisms. The oscillatory pressure waveform is damped by the inertia of the respiratory system. Atelectatic alveoli are less compliant and are exposed to higher oscillatory pressures compared to normally aerated alveoli. For a detailed review, we recommend “High-frequency oscillatory ventilation: mechanisms of gas exchange and lung mechanics” by J.J Pillow. Figure 1 was first published by Slutsky A.S. & Drazen J.M. in 2002 and adapted by Pillow J.J.15

diffusion coefficient of CO₂ (DCO₂). In HFOV without volume guarantee (VG), an increase in ΔP₀ results in increased V₀ and thus an increased CO₂ washout, similar to CMV (see “Ventilator technology and modalities” section). Changes in frequency during HFV also affect the V₀, but in an inverse relation, especially when the inspiratory time (t₁) is not constant. For example, increasing the frequency itself will promote CO₂ clearance, but the concomitant decrease in V₀ in balance may reduce CO₂ washout. As the latter effect follows nearly a quadratic function, the overall effect of an increase in frequency may be a decreased CO₂ clearance.

**Ventilator technology and modalities**

The three main ventilator modalities providing HFV: high-frequency oscillatory ventilation (HFOV), high-frequency flow interruption (HFFI), and high-frequency jet ventilation (HFJV), will be discussed in this paragraph. HFOV refers to techniques generating an active biphasic displacement of air during both inspiration and expiration. Initially, pressure oscillations were created with a piston pump or an electromagnetically driven loudspeaker membrane and a constant bias flow in the patient circuit. Membranes can create various waveforms and asymmetric inspiration-expiration (I:E) ratios, while piston pumps are limited to sine waves with an I:E ratio of 1:1. This principle of oscillation has been modified in contemporary hybrid ventilators that create full active expiration by using opposite in- and expiratory flows or positive and negative pressure sources.

HFFI uses short bursts of gas delivered directly into the ventilatory circuit, for example, by fast solenoid valves. Expiration is either passive or assisted by a venturi system, which assists the return of pressures to expiratory baseline and results in a modest active negative deflection.

HFJV uses rapid pulses of fresh gas produced by a pinch valve and released as a jet, either directly into the upper airway via a special endotracheal tube or into the Y-piece of the circuit. In contrast to HFOV, exhalation is passive, and to minimize the risk of gas trapping lower operating frequencies are often applied. The settings of the conventional ventilator (peak inspiratory pressure, positive end-expiratory pressure, t₁, and f), which is used in tandem, contribute to the mean airway pressure comparable to CMV. A majority of the available studies (bench, animal, and clinical) examined HFOV; this imbalance is reflected in the “Clinical use of HFV” and “Clinical trials” sections.

Most modern (hybrid) ventilators provide the option of simultaneous delivery of CMV and HFV, enabling the application of periodic sighs during HFV, which may assist in lung volume recruitment. However, if conventional sighs are necessary to maintain the optimal lung volume during HFV, this indicates that the selected CDP is probably set too low.

Modern hybrid ventilators also provide V₀ measurement at the Y-piece, enabling the calculation of DCO₂, and allowing for VG during HFV. During VG, the V₀ set by the clinician is stabilized despite varying lung compliance by automatic adjustments of the ΔP₀. Small cross-over studies in preterm infants have shown that adding VG stabilizes the V₀ and DCO₂, and thereby reduces the rate of hypo- and hypercarbia. Importantly, VG neutralizes changes in V₀ in response to changes in frequency. As a result, the effect of changes in frequency on CO₂ clearance during HFV with VG becomes similar to CMV.

Recent studies have shown that HFV ventilators do not perform equally, especially flow interrupters vs. membrane oscillators. There are significant differences between the set and delivered ΔP₀ and the delivered V₀ at different frequencies and conditions of the lung, which are relevant to the clinical application of HFV.

Finally, adequate humidification is essential to avoid airway injury due to insufficient gas conditioning at high flow rates, which are often necessary during HFV.

**HFV and lung protection**

As previously mentioned, HFV has been considered lung-protective due to the small tidal volume delivery, thereby...
minimizing alveolar overdistension (volutrauma). However, animal studies have indicated that reducing atelectasis during HFV also contributes to lung protection.\textsuperscript{32} If the underlying lung disease is characterized by alveolar collapse resulting in a low EELV, recruitment and subsequent stabilization of collapsed alveoli are essential for maximum lung protection during HFV. This concept is also referred to as the open lung or optimal lung volume ventilation strategy.

Figure 2 shows the pressure–volume (P/V) relationship of an individual alveolus. After a critical opening pressure is reached, the collapsed alveolus opens, immediately resulting in a large volume increase due to a decrease in lung compliance and an increase in Po is reached. As soon as lung volume approaches total lung capacity (TLC), the inflation limb flattens off. Note the apparent difference in lung volume between both limbs at identical pressures (hysteresis).

alveolar dead space. Moving back on the deflation limb, as pressures are reduced, PCO\textsubscript{2} will decrease again.\textsuperscript{31}

**CLINICAL USE OF HFV**

In clinical practice, HFV should be tailored to the underlying lung disease. HFV can be used in both recruitable and non-recruitable lung diseases. This distinction is, in our view, essential, as only the former will benefit from a lung recruitment procedure during HFV. Examples of recruitable diseases are respiratory distress syndrome (RDS), pneumonia, and meconium aspiration syndrome. In non-recruitable lung diseases, for example, lung hypoplasia after prolonged rupture of membranes or congenital diaphragmatic hernia, the focus should be on avoiding lung overdistension, which may lead to lung injury and air leak syndromes. Combinations of recruitable and non-recruitable conditions might occur. In infants with hypoplastic lung disease, V\textsubscript{E}/kg needs to be reduced in CMV to avoid severe VILI, which may lead to hypercapnia. HFOV, despite using small V\textsubscript{E}, often can maintain gas exchange potentially without excessive additional VILI.

HFV can be used as a primary or a rescue mode. When using primary HFV, infants failing non-invasive respiratory support are directly started on HFV. This approach is consistent with the concept that HFV aims to prevent lung injury and is not a modality to resolve lung injury. Rescue HFV is often started once other invasive ventilation modes fail to deliver adequate gas exchange or do so only at the expense of injurious ventilator settings. Herein, HFV is used to correct gas exchange and minimize the progression of lung injury.

**Continuous distending pressure**

The primary function of the CDP is to optimize EELV, thereby reducing possible VILI and intrapulmonary shunt, and improving gas exchange. If the patient is suffering from recruitable lung disease, the CDP is also used to reverse atelectasis. One of the crucial challenges in neonatology is monitoring changes in EELV non-invasively and safely at the bedside during lung recruitment. We recommend using oxygenation as an indirect tool to monitor lung recruitment (Fig. 4). This is based on the assumption that the recruitment of collapsed alveoli will reduce intrapulmonary right-to-left shunt and improve oxygenation. The CDP at the start of lung recruitment depends on whether HFV is used as a primary or rescue mode. When used as a primary mode, the recommended CDP at the start of HFV is around 8 mbar.\textsuperscript{39} If a patient is rescued from CMV failure, most clinicians start with a CDP set 2 mbar above the mean airway pressure used during CMV. Next, the
In acute (<72 h old) RDS, we recommend increasing the CDP in 2 mbar steps and waiting at least 3 min between the pressure steps or longer if oxygenation continues to improve. In neonates >72 h or with more heterogeneous lung disease, bigger steps (3–4 mbar) can be taken while leaving more time (up to 20 min) to assess the effect of each step on EELV. The CDP is stepwise increased until either the FiO2 is reached that defines an optimal EELV or no improvement in oxygenation is seen following 2–3 steps of CDP increase. The CDP at either of these conditions is called the opening CDP (Po). Once the lung is fully recruited, it is essential to back down with the CDP, moving down on the deflation limb of the pressure–volume curve, taking advantage of the hysteresis of the lung. The CDP is stepwise reduced, keeping the FiO2 fixed until oxygenation starts to deteriorate (closing CDP [Pc]). Next, the CDP is increased to the known Po and then reduced to 2 mbar above the Pc. This individual recruitment strategy tailors the applied CDP to the severity of (recruitable) lung disease.

Studies on what FiO2 best defines optimal lung recruitment are limited. In the acute phase of RDS, clinicians often aim for a FiO2 below 0.30. In the case of more heterogeneous lung disease, somewhat higher FiO2 is targeted. It is important to emphasize that the use of oxygenation to guide lung recruitment is hampered in newborns with an extra-pulmonary right-to-left shunt (e.g., persistent pulmonary hypertension of the newborn (PPHN), congenital heart disease). In severe PPHN, the FiO2 is not reduced during recruitment, aiming for a high arterial PaO2 instead.

Oxygenation-guided lung recruitment requires adequate online monitoring of changes in oxygenation. Possible options are pulse oximetry and transcutaneous PO2. In patients with non-recruitable lung disease, no attempts should be made to increase CDP for lung recruitment. Preferably, the CDP is kept below 10 mbar to avoid the risk of overdistension and subsequent air leaks. Poor oxygenation is primarily caused by extra-pulmonary right-to-left shunt.

In addition to oxygenation, some clinicians assess EELV using chest X-ray. However, studies have shown that the association between EELV based on chest X-ray and a SF6 washout technique is limited. For this reason, chest X-ray should primarily be used to assess tube position, presence of air leaks or atelectasis, and signs of hyperinflation. EELV can change during the clinical course. Therefore, a dynamic approach is needed to ensure that the optimal EELV is maintained during the course of lung disease.

**Oscillatory amplitude**

At the start of ventilation, a ΔPfl is set that results in slight oscillations of the chest, which usually results in a Vf around 2 ml/kg at a frequency of 10–12 Hz. Notably, the correlation between the delivered Vf and the actual PacCO2 is limited. Several conditions will impact the CO2 washout at any given ΔPfl. First, changes in the underlying lung disease or the position of ventilation on the P/V curve will influence compliance and thus affect Vf in HFV without VG. Second, overdistension with an increase in alveolar dead space will decrease CO2 clearance. Third, mucus in the airway or position of the tip of the endotracheal tube against the tracheal wall, may dampen the oscillation amplitude and thus result in a rise in PCO2.

Nonetheless, HFV is very efficient in removing CO2, and this increases the risk of unintended severe hypocapnia, which can compromise cerebral perfusion. Therefore, continuous transcutaneous monitoring of PCO2 or DCO2 is recommended as a guide for ΔPfl and frequency adjustments. To further reduce the risk of hypocapnia and diaphragmatic dysfunction, we suggest setting the amplitude low enough to allow for spontaneous breathing of the infant.

**Oscillatory frequency**

 Frequencies ranging from 8 to 15 Hz are used in daily clinical practice; however, a set frequency is rarely changed unless the amplitude reaches unconventional settings. The interaction between frequency and ventilation is quite complex; compliance, resistance, and inertia determine lung impedance (Z) and thereby ventilation at a specific frequency:

\[
|Z| = \sqrt{R^2 + \left(2\pi f \cdot l - \frac{1}{2\pi f C}\right)^2} \tag{19,53}
\]

Also, the transmission of the ΔPfl from the airway opening to the peripheral lung units is inversely related to the frequency. Therefore, using a higher frequency will result in a lower pressure cost of ventilation and smaller Vf, which may reduce the risk of barotrauma. This holds true until the corner frequency is reached above which the additional fall in transmitted ΔPfl is small. The corner frequency is inversely related to the time constant of the respiratory system (fC = \frac{1}{\pi fC}) and might serve as an appropriate target to minimize the pressure cost of HFV (Fig. 5). Low compliance lung disease with a short time constant might benefit from higher frequencies and high resistance lung disease from a lower frequency. However, increasing frequency is limited by decreasing ventilator performance.

**I:E ratio**

The I:E ratio can be set by the clinician in most HFV ventilators, and the most widely used settings are 1:1 or 1:2. Using a longer inspiration time will increase Vf and, thus, a decrease in PCO2 unless appropriate reductions are made to the oscillatory amplitude. Changing the I:E ratio will also affect the transmission of the mean airway pressure from the airway opening to the alveolar compartment. Using a 1:2 ratio will result in a significant drop in mean airway pressure at the alveolar level, especially at higher pressure amplitudes and higher frequencies. This drop

---

**Fig. 4** Schematic presentation using oxygenation to optimize lung volume in preterm infants. At the start (A), airway pressure is low, and FiO2 is high, indicating a high degree of atelectasis and intrapulmonary shunt. Over time, airway pressures are stepwise increased, resulting in alveolar recruitment, a reduction in intrapulmonary shunt, and an improvement in oxygenation. The latter will allow a stepwise reduction in FiO2, thus preventing hyperoxia. Airway pressure is increased until target FiO2 indicating optimal recruitment is reached or oxygenation no longer improves (B). The pressure level at point B is called the opening pressure (Po). Airway pressure is stepwise reduced until FiO2 starts to increase, indicating alveolar derecruitment (C). This pressure level is called the closing pressure (Pc). After re-opening collapsed alveoli with the known Po (D), airway pressure is set 2 mbar above Pc to ensure the stabilization of lung volume (E).

CDP is stepwise increased, and as oxygenation improves, the FiO2 is gradually reduced to keep the SpO2 within the intended target range. The size of the pressure steps and the time between each step depends on the underlying lung disease. Monitoring blood pressure during the recruitment procedure is also recommended in order to detect a reduction in cardiac output due to lung overdistension (see also “Complications” section). Other tools like the forced oscillation technique and electrical impedance tomography might also be useful in searching for the optimal CDP.

In patients with non-recruitable lung disease, no attempts should be made to increase CDP for lung recruitment. Preferably, the CDP is kept below 10 mbar to avoid the risk of overdistension and subsequent air leaks. Poor oxygenation is primarily caused by extra-pulmonary right-to-left shunt.
and lung model studies. Heterogeneous lung disease can probably be extubated from spontaneous breathing efforts. Some clinicians tend to switch narrow to the onset of expiratory\text{-}flation. During expiration, the airways may air trapping and underinflation. The corner frequency ($\Delta f$) following $|Z| = \sqrt{R^2 + \left(2\pi f \cdot l - \frac{1}{(2\pi f + C)}\right)^2}$ with the specific variables resistance ($R$), compliance ($C$), and inertance ($l$). The solid line represents the impedance/frequency relationship in a healthy lung; the dotted line represents elevated airway resistance; the dashed line reduced compliance. Smaller impedance with increasing frequency represents a lower pressure cost of ventilation and smaller $V_C$. The resonance frequency ($f_0$) with the lowest impedance can be calculated by $f_0 = \frac{1}{\sqrt{2\pi C_1}}$ and is marked with open rings. The corner frequency ($f_c$) is inversely related to the time constant of the respiratory system ($f_c = \frac{1}{\sqrt{2\pi C_1}}$), above $f_c$ (marked with squares) the additional fall in lung impedance is small and the dampening of $\Delta P_{alveoli}$ increases. Thus, low compliance lung disease (e.g., RDS) might benefit from higher frequencies ($>10\text{ Hz}$) and high resistance lung disease from a lower frequency ($<10\text{ Hz}$). However, increasing frequency is limited by decreasing ventilator performance.

Fig. 5  Concept of corner frequency in high-frequency ventilated neonates, according to Dorkin et al.19,53 Impedance ($Z$) is plotted against frequency ($f$) following $|Z| = \sqrt{R^2 + \left(2\pi f \cdot l - \frac{1}{(2\pi f + C)}\right)^2}$ with the specific variables resistance ($R$), compliance ($C$), and inertance ($l$). The solid line represents the impedance/frequency relationship in a healthy lung; the dotted line represents elevated airway resistance; the dashed line reduced compliance. Smaller impedance with increasing frequency represents a lower pressure cost of ventilation and smaller $V_C$. The resonance frequency ($f_0$) with the lowest impedance can be calculated by $f_0 = \frac{1}{\sqrt{2\pi C_1}}$ and is marked with open rings. The corner frequency ($f_c$) is inversely related to the time constant of the respiratory system ($f_c = \frac{1}{\sqrt{2\pi C_1}}$), above $f_c$ (marked with squares) the additional fall in lung impedance is small and the dampening of $\Delta P_{alveoli}$ increases. Thus, low compliance lung disease (e.g., RDS) might benefit from higher frequencies ($>10\text{ Hz}$) and high resistance lung disease from a lower frequency ($<10\text{ Hz}$). However, increasing frequency is limited by decreasing ventilator performance.19,53

is not observed when using a 1:1 ratio, which may lead to gas trapping, which is physically plausible and was found in animal and lung model studies. Is an I:E ratio of 2:5 (i.e., 40%) might be a favorable compromise between the risks of air trapping and underinflation. During expiration, the airways may narrow to the onset of expiratory-flow limitation, and $CO_2$ levels reach a plateau and cannot be further reduced. This effect can occur dynamically in some lung areas resulting in hyperinflation (i.e., regional air trapping).19,61,63,64

Weaning and extubation
Similar to CMV, patients on HFV should be weaned to non-invasive support as soon as possible. Anticipating improvement of the pulmonary condition, lowering the CDP (especially at low FiO$_2$ requirements) should be attempted at least every 12–24 h. Thereby, optimal EELV is achieved with the lowest possible CDP to avoid progressive hyperinflation leading to lung injury. The $\Delta P_{alveoli}$ is weaned based on the PCO$_2$ and the presence of spontaneous breathing efforts. Some clinicians tend to switch back from HFV to CMV for weaning, but extubation directly from HFV is also feasible. The optimal settings from which to extubate are the subject of ongoing research. For infants with RDS, extubation could be attempted once the CDP reaches 8 mbar and the FiO$_2$ is below 0.30. Infants with more heterogeneous lung disease can probably be extubated from higher settings.

Complications
HFV has been associated with several complications. Initial trials showed an increase in the risk of intraventricular hemorrhage (IVH), which might have been due to the very effective removal of CO$_2$ and lack of adequate PCO$_2$ monitoring, but could also have resulted from hampered venous return by higher intra-thoracic pressure, leading to hypocapnia and unstable brain perfusion. More recent studies in extremely preterm infants reported no increase in IVH compared with CMV. A second reported complication of HFV is an increase in the incidence of air leaks. The application of higher CDP during HFV may also impact hemodynamic stability by impeding venous return. This effect depends on the compliance of the lung and the level of CDP. Higher CDPs can be applied to low-compliant lungs without compromising hemodynamics. Cohort studies in preterm infants showed that individualized lung recruitment does not significantly impact cardiac output and venous return, but overdistension reduces right ventricular output. If a drop in blood pressure does occur during lung recruitment, this should be considered a serious sign of lung overdistension.

CLINICAL TRIALS
HFV in RDS
HFV has mainly been studied in premature infants with RDS. A total of 19 studies, including 4096 infants, have compared primary HFV to CMV. Meta-analyses showed a modest but significant reduction in BPD, death or BPD, and severe retinopathy of prematurity. However, the effect on BPD is weakened by the inconsistency across trials, some showing a benefit of HFV, while more recent trials reported no or small differences between HFV and CMV. Several trials, but not all, also reported an increase in air leaks.

Several attempts have been made to explain this heterogeneity across trials, but these are hampered by insufficient data presented in the results section of most trials. Based on the available data, it seems that differences in patient characteristics, supportive therapies, ventilator technology, and the ventilation strategy used during both HFV and CMV are largely responsible for the heterogeneous effect of HFV on BPD. In some trials, HFV was not combined with a high lung volume strategy and was only applied during part of the ventilation period. On the other hand, the CMV modes in the available trials differed considerably in the applied frequency and pressure settings. These differences may, at least in part, have compromised the lung-protective potential of both modalities and thus the effect on BPD. Figure 6 shows a forest plot sub-grouped according to ventilation strategies using criteria described by Thome et al. It seems that using more protective high-rate CMV results in similar BPD rates as HFV. These findings emphasize the importance of the ventilation strategy during both HFV and CMV and the need to optimize the ventilator settings in both modalities.

To date, limited information on the long-term pulmonary outcome is available. In a follow-up study of the UKOS trial, a significant benefit in adolescent lung function was observed favoring HFOV, even though BPD rates were similar in the HFOV and CMV groups. The HFOV group also had superior results in some cognitive tasks. This study suggests long-term benefits of primary HFV in preterm infants with RDS, regardless of the BPD rating at 36 weeks of gestational age.

Surfactant application during HFOV
A recently published study investigated the impact of a recruitment procedure applied during HFOV on the efficacy of surfactant treatment via an endotracheal tube. Recruitment with HFOV prior to surfactant administration resulted in a reduced need for mechanical ventilation in the first 72 h of life (primary end-point) but no reduction of BPD. Several methodological
Limitations, however, prevent firm conclusions, and it is also unclear how this method compares to avoiding intubation by using the less invasive surfactant application method (LISA).

HFJV in RDS

To date, four randomized studies comparing HFJV to CMV in preterm infants with RDS are published,93-96 of which three are analyzed in detail in a Cochrane review.97 Although the results suggest a lower BPD rate in the HFJV groups, drawing conclusions is difficult, as the conventional ventilation protocols were not specified or optimized, and the total number of cases was small. To our knowledge, no studies compare the clinical effects of HFOV to HFJV.98

HFV in other lung diseases

Congenital diaphragmatic hernia (CDH). Aside from retrospective studies and case series documenting the widespread use of HFOV in newborns with CDH,99-102 to date the VICI trial is the only prospective randomized trial comparing CMV to HFOV.103 This study failed to show a benefit of HFOV over CMV but instead reported a trend to a higher rate of the combined outcome of death or BPD in the HFOV group. This finding might be explained by the fact that lung hypoplasia caused by CDH is a non-recruitable disease, and applying higher CPAPs will not offer the same benefits as in recruitable lung diseases.

Acute respiratory failure at term. Only a few studies have explored the use of HFV in acute respiratory failure in term infants.95,104,105 Most included infants who suffered from meconium aspiration syndrome, respiratory distress, and pneumonia. In ~25–50% of infants with severe respiratory failure, switching from CMV to HFV resulted in a short-term improvement of gas exchange.106 Furthermore, combining HFV with inhaled NO provided the highest rate of responders in patients with severe PPHN.99 However, these studies were underpowered to evaluate a possible impact on more meaningful clinical outcomes.

Air leak syndrome. Although HFV may be associated with an increased risk of air leaks in preterm infants with RDS, some studies have explored the possible benefit of HFV in already established air leak syndrome. Keszler et al.107 demonstrated the benefit of HFJV compared to rapid-rate CMV with inspiratory times between 0.20 and 0.35 s. Clark et al.108 reported benefits from HFOV in infants with pulmonary interstitial emphysema. Using lower frequencies (5–6 Hz) and an I:E ratio of 1:2 might also be beneficial in established emphysema.109

CURRENT PRACTICE AND OUTLOOK

Currently, only a minority of neonatal units use HFV as the primary mode. More frequently, it is used as rescue ventilation when CMV is failing, or high settings are needed.13 However, rescue use of HFV has not been studied sufficiently and should be addressed in future research.

The use of HFV in infants with surfactant deficiency and pulmonary immaturity has been extensively studied. However, its use in other causes of respiratory failure, especially in term newborns, is poorly studied. Future multicenter studies are...
REFERENCES

1. van Kaam, A. H. et al. Modes and strategies for providing conventional mechanical ventilation in neonates. Pediatr. Res. 1–6. https://doi.org/10.1038/s41390-019-0704-1 (2019).
2. Lunkenheimer, P. P. et al. Application of transstrachael pressure oscillations as a modification of “diffusion respiration”. Br. J. Anaesth. 44, 627–628 (1972).
3. Bohn, D. J. et al. Ventilation by high-frequency oscillation. J. Appl. Physiol. 48, 710–716 (1980).
4. van Kaam, A. H. et al. Positive pressure ventilation with the open lung concept optimizes gas exchange and reduces ventilator-induced lung injury in newborn piglets. Pediatr. Res. 53, 245–253 (2003).
5. Yoder, B. A., Siler-Khodr, T., Winter, V. T. & Coalson, J. J. High-frequency oscillatory ventilation. Am. J. Respir. Crit. Care Med. 162, 1867–1876 (2000).
6. Heicher, D. A., Kasting, D. S. & Harrod, J. R. Prospective clinical comparison of two methods for mechanical ventilation of neonates: Rapid rate and short inspiratory time versus slow rate and long inspiratory time. J. Pediatr. 98, 957–961 (1981).
7. OCTAVE Study Group. Multicentre randomised controlled trial of high against low frequency positive pressure ventilation. Arch. Dis. Child. 76, 770–775 (1992).
8. Pohlandt, F. et al. Decreased incidence of extra-alveolar air leakage or death prior to air leakage in high versus low rate positive pressure ventilation: results of a randomised seven-centre trial in preterm infants. Eur. J. Pediatr. 151, 904–909 (1992).
9. Amini, E. et al. Comparison of high frequency positive pressure mechanical ventilation (HFPPV) with conventional method in the treatment of neonatal respiratory failure. Iran. Red. Crescent Med. J. 15, 183–186 (2013).
10. Greenough, A., Rossor, T. E., Sundaresan, A., Murthy, V. & Milner, A. D. Synchronized mechanical ventilation for respiratory support in newborn infants. Cochrane Database Syst. Rev. 9, CD000456 (2016).
11. Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 163, 1723–1729 (2001).
12. Soll, R. F. et al. Obstetric and neonatal care practices for infants 501 to 1500 g from 2000 to 2009. Pediatrics 132, 222–228 (2013).
13. van Kaam, A. H., Rimensberger, P. C., Borensztajn, D., De Jaegere, A. P. & Neovent Study Group. Ventilation practices in the neonatal intensive care unit: a cross-sectional study. J. Pediatr. 157, 767.e1–3 (2010).
14. Gerstmann, D. R., Fouke, J. M., Winter, D. C., Taylor, A. F. & deLemos, R. A. Proximal, tracheal, and alveolar pressures during high-frequency oscillatory ventilation in a normal rabbit model. Pediatr. Res. 28, 367–373 (1990).
15. Pillow, J. J. High-frequency oscillatory ventilation: mechanisms of gas exchange and lung mechanics. Crit. Care Med. 33, S135–S141 (2005).
16. Rossing, T. H. et al. Tidal volume and frequency dependence of carbon dioxide elimination by high-frequency ventilation. N. Engl. J. Med. 305, 1375–1379 (1981).
17. Slutsky, A. S. & Drazen, J. M. Ventilation with small tidal volumes. N. Engl. J. Med. 347, 630–631 (2002).
18. Boynton, B. R. et al. Gas exchange in healthy rabbits during high-frequency oscillatory ventilation. J. Appl. Physiol. 66, 1343–1351 (1989).
19. Venegas, J. G. & Fredberg, J. J. Understanding the pressure cost of ventilation: why does high-frequency ventilation work? Crit. Care Med. 22, 549–557 (1994).
20. Jirapaet, K. S., Kiatkachusuk, P., Kolatat, T. & Srisuparb, P. Comparison of high-frequency flow interruption ventilation and hyperventilation in persistent pulmonary hypertension of the newborn. Respir. Care 46, 586–594 (2001).
21. McCarthy, S. E. & Asselen, J. M. High-frequency jet and oscillatory ventilation for neonates: which strategy and when? Respir. Care Clin. N. Am. 12, 453–467 (2006).
22. Carpi, M. F. High-frequency jet ventilation in preterm infants: is there still room for it? Respir. Care 62, 997–998 (2017).
23. Ican, B., Duman, N., Tuzun, F., Kumral, A. & Ozkan, H. Impact of volume guarantee on high-frequency oscillatory ventilation in preterm infants: a randomized crossover clinical trial. Neonatology 108, 277–282 (2015).
24. Belteki, G. & Morley, C. J. High-frequency oscillatory ventilation with volume guarantee: a single-centre experience. Arch. Dis. Child. Fetal Neonatal Ed. 104, 384 (2018).
25. Tingay, D. G. et al. Are all oscillators created equal? in vitro performance characteristics of eight high-frequency oscillatory ventilators. Neonatology 108, 220–228 (2015).
26. Graziosi, S., Karam, O. & Rimensberger, P. C. New generation neonatal high frequency ventilators: effect of oscillatory frequency and working principles on performance. Respir. Care 60, 363–370 (2015).
27. Bauer, K. & Brückler, C. The role of ventilation frequency in airway reopening. J. Biomech. 42, 1108–1113 (2009).
28. Schulze, A. Respiratory gas conditioning and humidification. Clin. Perinatol. 34, 19–33 (2007).
29. Schrifffmann, H. et al. Determination of airway humidification in high-frequency oscillatory ventilation using an artificial neonatal lung model. Comparison a heated humidifier a heat and moisture exchanger. Intensive Care Med. 25, 997–1002 (1999).
30. Cicco, L. E., Heard, S. O., Griffiths, E. & Nash, G. Overwhelming necrotizing tracheobronchitis due to inadequate humidification during high-frequency jet ventilation. Chest 100, 268–269 (1991).
31. Boros, S. J. et al. Necrotizing tracheobronchitis: a complication of high-frequency ventilation. J. Pediatr. 109, 95–100 (1986).
32. McCulloch, P. R., Forkert, P. G. & Froese, A. B. Lung volume maintenance prevents lung injury during high frequency oscillatory ventilation in surfactant-deficient rabbits. Am. Rev. Respir. Dis. 137, 1185–1192 (1988).
33. Staub, N. C., Nagano, H. & Pearce, M. L. Pulmonary edema in dogs, especially the hind limb of the pressure-volume relationship in infants during high-frequency oscillatory ventilation. J. Pediatr. 97, 651–659 (1980).
34. Miedema, M. et al. Effect of nasal continuous and biphasic positive airway pressure on lung volume in preterm infants. J. Pediatr. 162, 691–697 (2013).
35. Tingay, D. G. et al. Gradual aeration at birth is more lung protective than a sustained inflation in preterm lambs. Am. J. Respir. Crit. Care Med. https://doi.org/10.1164/rccm.201807-1397OC (2019).
36. Hickling, K. G. Best compliance during a decremental, but not incremental, positive end-expiratory pressure trial is related to open-lung positive end-expiratory pressure. Am. J. Respir. Crit. Care Med. 163, 69–78 (2001).
37. Rimensberger, P. C., Pristine, G., Mullens, J. B. M., Cox, P. N. & Slutsky, A. S. Lung recruitment during small tidal volume ventilation allows minimal positive end-expiratory pressure without augmenting lung injury. Crit. Care Med. 27, 1940–1945 (1999).
38. Tingay, D. G., Mills, J. F., Morley, C. J., Pellicano, A. & Dargaville, P. A. The deflation limb of the pressure-volume relationship in infants during high-frequency ventilation. Am. J. Respir. Crit. Care Med. 173, 414–420 (2006).
39. De Jaegere, A., van Veemen, M. B., Michiels, A. & van Kaam, A. H. Lung recruitment using oxygenation during open lung high-frequency ventilation in preterm infants. Am. J. Respir. Crit. Care Med. 174, 639–645 (2006).
40. De Jaegere, A. P., Deurloo, E. E., van Rijn, R. R., Offringer, M. & van Kaam, A. H. Individualized lung recruitment during high-frequency ventilation in preterm infants is not associated with lung hyperinflation and air leaks. Eur. J. Pediatr. 175, 1085–1090 (2016).
41. Miedema, M., de Jongh, F. H., Frierichs, I., van Veenendaal, M. B. & van Kaam, A. H. The effect of airway pressure and oscillation amplitude on ventilation in preterm infants. Eur. Respir. J. 40, 479–484 (2012).
42. Miedema, M., de Jongh, F. H., Frierichs, I., van Veenendaal, M. B. & van Kaam, A. H. Regional respiratory time constants during lung recruitment in high-frequency oscillatory ventilated preterm infants. Intensive Care Med. 38, 294–299 (2012).
61. Solway, J., Rossing, T. H., Saari, A. F. & Drazen, J. M. Expiratory flow separation, an important mechanism in the formation of mean pulmonary pressure during high-frequency oscillatory ventilation. Pediatr. Critical Care Med. 15, 1213–1218 (1998).

62. Saari, A. F., Rossing, T. H., Solway, J. & Drazen, J. M. Lung in high-frequency oscillation. Pediatr. Pulmonol. 26, 265–272 (1998).

63. Thome, U., Topfer, A., Schaller, P. & Pohlant, F. Effects of mean airway pressure on lung volume during high-frequency oscillatory ventilation of preterm infants. Am. J. Respir. Crit. Care Med. 157, 1213–1218 (1998).

64. Harris, R. S. Pressure-volume curves of the respiratory system. Am. J. Respir. Crit. Care Med. 157, 1213–1218 (1998).

65. Gonzalez-Pacheco, N., Sanchez-Luna, M., Ramos-Navarro, C., Navarro-Patiño, N. & de la Blanca, A. R-S. Using very high frequencies with very low lung volumes during high-frequency oscillatory ventilation to protect the immature lung. A pilot study. J. Perinatol. 36, 306–310 (2016).

66. Fredberg, J. J., Glass, G. M., Boynton, B. R. & Frantz, I. D. Factors influencing mechanical performance of neonatal high-frequency ventilators. J. Appl. Physiol. 62, 2485–2490 (1987).

67. Sánchez-Luna, M. et al. Effect of the I/E ratio on CO2 removal during high-frequency oscillatory ventilation with volume guarantee in a neonatal animal model of RDS. Eur. J. Pediatr. 175, 1343–1351 (2016).

68. Bush, E. H., Spahn, D. R., Niederer, P. F. & Schmid, E. R. Flow separation, an important mechanism in the formation of mean pulmonary pressure during high-frequency oscillatory ventilation. J. Biomech. Eng. 111, 17–23 (1989).

69. Thome, U. & Pohlant, F. Effect of the T/TE ratio on mean intratracheal pressure measurements by antero-posterior chest X-ray and the SF6 washout technique in mechanically ventilated infants. Pediatr. Pulmonol. 26, 265–272 (1998).

70. Thome, U. H. et al. Influence of PaCO2 control on clinical and neurodevelop-mental outcomes of extremely low birth weight infants. Neonatology 221–230. https://doi.org/10.1159/000485828 (2018).

71. Hochwald, O. et al. Continuous noninvasive carbon dioxide monitoring in neonates: from theory to standard of care. Pediatrics 144, e20183640 (2019).

72. Schäfer, C., Schumann, S., Fuchs, H. & Klotz, D. Carbon dioxide diffusion coeffi- cient in noninvasive high-frequency oscillatory ventilation. Pediatr. Pulmonol. 54, 759–764 (2019).

73. Vento, G. et al. Efficacy of exogenous surfactant during conventional and high-frequency oscillatory ventilation in preterm infants with RDS. Acta Bio-Med. Atenei Parm. 84, 25–27 (2013).

74. Dorkin, H. L. et al. Respiratory system impedance from 4 to 40 Hz in paralyzed intubated infants with respiratory disease. J. Clin. Invest. 72, 903–910 (1983).

75. Pillow, J. J., Neil, H., Wilkinson, M. H. & Ramsden, C. D. Effect of I/E ratio on mean alveolar pressure during high-frequency oscillatory ventilation. J. Appl. Physiol. 87, 407–414 (1999).

76. Pillow, J. J., Sly, P. D., Hants, Z. & Bates, J. H. T. Dependence of intrapulmonary pressure amplitudes on respiratory mechanics during high-frequency oscillatory ventilation in preterm lambs. Pediatr. Res. 52, 538–544 (2002).

77. González-Pacheco, N., Sánchez-Luna, M., Ramos-Navarro, C., Navarro-Patiño, N. & de la Blanca, A. R-S. Using very high frequencies with very low lung volumes during high-frequency oscillatory ventilation to protect the immature lung. A pilot study. J. Perinatol. 36, 306–310 (2016).

78. Fredberg, J. J., Glass, G. M., Boynton, B. R. & Frantz, I. D. Factors influencing mechanical performance of neonatal high-frequency ventilators. J. Appl. Physiol. 62, 2485–2490 (1987).

79. Sánchez-Luna, M. et al. Effect of the I/E ratio on CO2 removal during high-frequency oscillatory ventilation with volume guarantee in a neonatal animal model of RDS. Eur. J. Pediatr. 175, 1343–1351 (2016).

80. Bush, E. H., Spahn, D. R., Niederer, P. F. & Schmid, E. R. Flow separation, an important mechanism in the formation of mean pulmonary pressure during high-frequency oscillatory ventilation. J. Biomech. Eng. 111, 17–23 (1989).

81. Thome, U. & Pohlant, F. Effect of the T/TE ratio on mean intratracheal pressure measurements by antero-posterior chest X-ray and the SF6 washout technique in mechanically ventilated infants. Pediatr. Pulmonol. 26, 265–272 (1998).

82. Solway, J., Rossing, T. H., Saari, A. F. & Drazen, J. M. Expiratory flow limitation and dynamic pulmonary hyperinflation during high-frequency ventilation. J. Appl. Physiol. 60, 2071–2078 (1986).

83. Saari, A. F., Rossing, T. H., Solway, J. & Drazen, J. M. Lung inflation during high-frequency ventilation. Am. Rev. Respir. Dis. 129, 333–336 (1984).

84. Vento, G. et al. HFV in premature neonates: effects on pulmonary mechanics and epithelial lining fluid cytokines. A randomized controlled trial. Intensive Care Med. 31, 463–470 (2005).

85. Thome, U. H., Carlo, W. A. & Pohlant, F. Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch. Dis. Child. Fetal Neonatal Ed. 93, F252–F256 (2008).

86. Solva, V. et al. First intention high-frequency oscillatory and conventional mechanical ventilation in preterm infants without antenatal glucocorticoid prophylaxis. Pediatr. Crit. Care Med. 13, 72–79 (2012).

87. Thome, U. H., Carlo, W. A. & Pohlant, F. Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch. Dis. Child. Fetal Neonatal Ed. 90, F466–F473 (2005).

88. Thome, U. H., Carlo, W. A. & Pohlant, F. Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch. Dis. Child. Fetal Neonatal Ed. 90, F466–F473 (2005).

89. van Kaam, A. H., Rimensberger, P. C. Lung-protective ventilation strategies in neonatology: what do we know what do we need to know? Crit. Care Med. 35, 1025–1031 (2007).

90. Thome, U. H., Carlo, W. A. & Pohlant, F. Ventilation strategies and outcome in randomised trials of high frequency ventilation. Arch. Dis. Child. Fetal Neonatal Ed. 90, F466–F473 (2005).

91. Zivanovic, S. et al. Late outcomes of a randomized trial of high-frequency oscillation in neonates. N. Engl. J. Med. 370, 1121–1130 (2014).

92. Vento, G. et al. Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, blinded, controlled trial. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(20)30179-X (2020).
93. Carlo, W. A., Siner, B., Chatburn, R. L., Robertson, S. & Martin, R. J. Early randomized intervention with high-frequency jet ventilation in respiratory distress syndrome. *J. Pediatr.* **117**, 765–770 (1990).

94. Wiswell, T. E. et al. High-frequency jet ventilation in the early management of respiratory distress syndrome is associated with a greater risk for adverse outcomes. *Pediatrics* **98**, 1035–1043 (1996).

95. Keszer, M. et al. Multicenter controlled clinical trial of high-frequency jet ventilation in preterm infants with uncomplicated respiratory distress syndrome. *Pediatrics* **100**, 593–599 (1997).

96. Carlo, W. A., Chatburn, R. L. & Martin, R. J. Randomized trial of high-frequency jet ventilation versus conventional ventilation in respiratory distress syndrome. *J. Pediatr.* **110**, 275–282 (1987).

97. Bhuta, T. & Henderson-Smart, D. J. Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants. *Cochrane Database Syst. Rev.* CD000328. https://doi.org/10.1002/14651858.CD000328 (2000).

98. Ethawi, Y. H., Abou Mehrem, A., Minski, J., Ruth, C. A. & Davis, P. G. High frequency jet ventilation versus high frequency oscillatory ventilation for pulmonary dysfunction in preterm infants. *Cochrane Database Syst. Rev.* CD010548. https://doi.org/10.1002/14651858.CD010548.pub2 (2016).

99. Kinsella, J. P. et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. *J. Pediatr.* **131**, 55–62 (1997).

100. Migliazza, L. et al. Retrospective study of 111 cases of congenital diaphragmatic hernia treated with early high-frequency oscillatory ventilation and presurgical stabilization. *J. Pediatr. Surg.* **42**, 1526–1532 (2007).

101. Ng, G. Y. et al. Reduction in ventilator-induced lung injury improves outcome in congenital diaphragmatic hernia. *Pediatr. Surg. Int.* **24**, 145–150 (2008).

102. Reyes, C. et al. Delayed repair of congenital diaphragmatic hernia with early high-frequency oscillatory ventilation during preoperative stabilization. *J. Pediatr. Surg.* **33**, 1014–1016 (1998).

103. Snoek, K. G. et al. Conventional mechanical ventilation versus high-frequency oscillatory ventilation for congenital diaphragmatic hernia: a randomized clinical trial (The VICI-trial). *Ann. Surg.* **263**, 867–874 (2016).

104. Carter, J. M. et al. High-frequency oscillatory ventilation and extracorporeal membrane oxygenation for the treatment of acute neonatal respiratory failure. *Pediatrics* **85**, 159–164 (1990).

105. Clark, R. H. High-frequency ventilation. *J. Pediatr.* **124**, 661–670 (1994).

106. Ben Jaballah, N. et al. High-frequency oscillatory ventilation in term and near-term infants with acute respiratory failure: early rescue use. *Am. J. Perinatol.* **23**, 403–411 (2006).

107. Keszer, M. et al. Multicenter controlled trial comparing high-frequency jet ventilation and conventional mechanical ventilation in newborn infants with pulmonary interstitial emphysema. *J. Pediatr.* **119**, 85–93 (1991).

108. Clark, R. H. et al. High frequency oscillatory ventilation with low oscillatory frequency in pulmonary interstitial emphysema. *Neonatology* **104**, 243–249 (2013).

109. Fok, T. F., Ng, P. C., Wong, W., Lee, C. H. & So, K. W. High frequency oscillatory ventilation in infants with increased intra-abdominal pressure. *Arch. Dis. Child. Fetal Neonatal Ed.* **76**, F123–F125 (1997).

110. Masahata, K. et al. Risk factors for pneumothorax associated with isolated congenital diaphragmatic hernia: results of a Japanese multicenter study. *Pediatr. Surg. Int.* **36**, 669–677 (2020).

**AUTHOR CONTRIBUTIONS**

B.W.A. drafted the article, Figs. 5 and 6. A.v.K. wrote the chapter on ventilator technology, Figs. 2, 3, and 4. A.v.K., R.H., D.K., and U.H.T. revised the manuscript and contributed to subchapters. All authors state, that they did not receive any financial support for their contributions to this manuscript.

**FUNDING**

Open Access funding enabled and organized by Projekt DEAL.

**COMPETING INTERESTS**

The authors declare no competing interests.

**ADDITIONAL INFORMATION**

Correspondence and requests for materials should be addressed to U.H.T.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.